No Data
Alumis to Participate in Guggenheim's Inaugural Healthcare Innovation Conference
Alumis Initiated at Outperform by Baird
Baird Initiates Alumis(ALMS.US) With Buy Rating, Announces Target Price $25
Alumis' Investigational Lead Candidate Supports Superior Profile Than Bristol Myers' Commercialized Drug, Analyst Sees 170% Stock Upside
This Gilead Sciences Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
Express News | Alumis Inc. : H.c. Wainwright Initiates Coverage With Buy Rating and Target Price $30
No Data
No Data
